Eszopiclone versus zopiclone in the treatment of insomnia

Clinics

Volumn 71, Issue 1, 2016, Pages 5-9

  Pinto, Luciano Ribeiro ^a   Bittencourt, Lia Rita Azeredo ^a   Treptow, Erika Cristine ^a   Braga, Luciano Rotella ^a   Tufik, Sergio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Eszopiclone; Insomnia; Polysomnography; Zopiclone

Indexed keywords

AZABICYCLO DERIVATIVE; ESZOPICLONE; HYPNOTIC SEDATIVE AGENT; PIPERAZINE DERIVATIVE; ZOPICLONE;

ADULT; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSGEUSIA; FEMALE; HEADACHE; HUMAN; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AZABICYCLO COMPOUNDS; DOUBLE-BLIND METHOD; DYSGEUSIA; ESZOPICLONE; FEMALE; HEADACHE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PIPERAZINES; POLYSOMNOGRAPHY; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957591658     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2016(01)02     Document Type: Article

References (20)

1. Castro LS, Poyares D, Leger D, Bittencourt L, Tufik S. Objective prevalenceof insomnia in the Sao Paulo, Brazil epidemiologic sleep study.Ann Neurol. 2013;74(4):537-46, http://dx.doi.org/10.1002/ana.23945.
2. Fava GA, Grandi S, Canestrari R, Molnar G. Prodromal symptoms inprimary major depressive disorder. J Affect Disord.1990;19(2):149-52,http://dx.doi.org/10.1016/0165-0327(90)90020-9.
3. McCall WV. A psychiatric perspective on insomnia. J Clin Psychiatry.2001;62 (Suppl 10)27-32.
4. National Sleep Foundation. Sleep in America: A survey of US adults.A report prepared by the Gallup Organization for the National SleepFoundation. Los Angeles 1991.
5. Roth T. Insomnia: Definition, Prevalence, Etiology, and Consequences.J Clin Sleep Med. 2007 Aug 15; 3(5 Suppl): S7–S10.
6. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances andpsychiatric disorders. An opportunity for prevention? JAMA: 1989;262(11):1479-84, http://dx.doi.org/10.1001/jama.1989.03430110069030.
7. Ancoli-Israel S. The impact and prevalence of chronic insomnia and othersleep disturbances associated with chronic illness. The American journalof managed care. 2006;12(Suppl 8):S221-9.
8. Pinto Jr LR, Alves RC, Caixeta E, Fontenelle JA, Bacellar A, Poyares D,et al. New guidelines for diagnosis and treatment of insomnia. ArqNeuropsiquiatr. 2010;68(10):666-75, http://dx.doi.org/10.1590/S0004-282X2010000400038.
9. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugsfor insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.Drug Saf. 2003;26(4):261-82, http://dx.doi.org/10.2165/00002018-200326040-00004.
10. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN.Effectiveness of non-benzodiazepine hypnotics in treatment of adultinsomnia: meta-analysis of data submitted to the Food and Drug Administration.BMJ. 2012;345:e8343, http://dx.doi.org/10.1136/bmj.e8343.
11. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of theefficacy and safety of eszopiclone over 12 months in patients with chronicprimary insomnia. Sleep Med. 2005;6(6):487-95, http://dx.doi.org/10.1016/j.sleep.2005.06.004.
12. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al.Sustained efficacy of eszopiclone over 6 months of nightly treatment:results of a randomized, double-blind, placebo-controlled study in adultswith chronic insomnia. Sleep. 2003;26(7):793-9.
13. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, et al.Nightly treatment of primary insomnia with eszopiclone for six months:effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959-68.
14. Boyle J, Groeger JA, Paska W, Groeger JA, Paska W, Cooper JA, Rockett C,Jones S, Gandhi P, et al. A method to assess the dissipation of the [corrected]residual effects of [corrected] hypnotics: eszopiclone versus zopiclone.J Clin Psychopharmacol. 2012;32(5):704-9, http://dx.doi.org/10.1097/JCP.0b013e3182664eec.
15. American Psychological Association. Diagnostic and statistical manual ofmental disorders (4th ed.). Washington, D.C., 1994.
16. American Academy of Sleep Medicine AASM. The AASM Manual for theScoring of Sleep and Associated Events: American Academy of SleepMedicine; 2005.
17. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia SeverityIndex as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297-307, http://dx.doi.org/10.1016/S1389-9457(00)00065-4.
18. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. ThePittsburgh Sleep Quality Index: a new instrument for psychiatric practiceand research. Psychiatry Res. 1989;28(2):193-213, http://dx.doi.org/10.1016/0165-1781(89)90047-4.
19. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G,et al. Cognitive behavioral therapy vs zopiclone for treatment ofchronic primary insomnia in older adults: a randomized controlledtrial. JAMA. 2006;295(24):2851-8, http://dx.doi.org/10.1001/jama.295.24.2851.
20. Sukys-Claudino L, Moraes WAS, Tufik S, Poyares D. Novos sedativoshipnóticos. Rev Bras Psiquiatr. 2010;32(3):288-93, http://dx.doi.org/10.1590/S1516-44462010000300014.